CardioNet, Inc. Announces The Launch Of Its Next Generation MCOT™ Device
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology
company with a current focus on the diagnosis and monitoring of cardiac
arrhythmias, today announced the launch of its next generation Mobile
CardioNet, Inc. (NASDAQ:BEAT), a leading wireless medical technology company with a current focus on the diagnosis and monitoring of cardiac arrhythmias, today announced the launch of its next generation Mobile Cardiac Outpatient Telemetry device. Joseph Capper, President and Chief Executive Officer of CardioNet, commented: “The launch of this state-of-the-art system is further evidence of our commitment to advancing cardiac monitoring solutions to meet the evolving needs of physicians and their patients. The introduction of this new device enhances our leadership position in cardiac monitoring with capabilities to improve the patient experience and reduce costs. The new device will enable physicians to offer the product in their offices, shortening the time to patient activation. The monitor also incorporates instructional video which, combined with the recent launch of an online tutorial, will further improve the patient experience. The cost to manufacture this product is approximately one-third less compared to our current system. Additionally, the product’s flexible design will facilitate the seamless introduction of planned future enhancements.” About CardioNet CardioNet is a leading provider of ambulatory, continuous, real-time outpatient management solutions for monitoring relevant and timely clinical information regarding an individual’s health. CardioNet’s initial efforts are focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders, with a solution that it markets as Mobile Cardiac Outpatient Telemetry TM (MCOT TM). More information can be found at http://www.cardionet.com. Forward-Looking Statements This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our growth prospects, the prospects for our products and our confidence in the Company’s future. These statements may be identified by words such as “expect,” “may,” “anticipate,” “possible,” “estimate,” “potential,” “intend,” “plan,” “believe,” “forecast,” “promises” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of them, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effectiveness of our efforts to address operational initiatives, including cost savings initiatives that affect our business, changes to insurance coverage, relationships with our government and commercial payors and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services and patent protection, adverse regulatory action and litigation success. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.